Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
Instil Bio (Nasdaq: TIL) and ImmuneOnco Biopharmaceuticals (HKEX: 1541.HK) announced they will co-host an investor and analyst breakfast event in Chicago on May 31, 2025. The event, scheduled from 8:00 to 9:30 am CT near McCormick Convention Center, will feature company management and a key opinion leader in immuno-oncology. They will discuss the PD-(L)1xVEGF bispecific antibody landscape and provide clinical trial updates. Interested investors and analysts can register by emailing [email protected].
Instil Bio (Nasdaq: TIL) e ImmuneOnco Biopharmaceuticals (HKEX: 1541.HK) hanno annunciato che co-organizzeranno un evento colazione per investitori e analisti a Chicago il 31 maggio 2025. L'evento, previsto dalle 8:00 alle 9:30 ora centrale, si terr脿 nei pressi del McCormick Convention Center e vedr脿 la partecipazione del management delle aziende e di un esperto di rilievo nel campo dell'immuno-oncologia. Verranno discussi il panorama degli anticorpi bispecifici PD-(L)1xVEGF e aggiornamenti sui trial clinici. Gli investitori e analisti interessati possono registrarsi scrivendo a [email protected].
Instil Bio (Nasdaq: TIL) y ImmuneOnco Biopharmaceuticals (HKEX: 1541.HK) anunciaron que coorganizar谩n un desayuno para inversores y analistas en Chicago el 31 de mayo de 2025. El evento, programado de 8:00 a 9:30 am CT cerca del McCormick Convention Center, contar谩 con la presencia de la direcci贸n de las compa帽铆as y un l铆der de opini贸n clave en inmuno-oncolog铆a. Se discutir谩n el panorama de anticuerpos bispec铆ficos PD-(L)1xVEGF y se proporcionar谩n actualizaciones sobre ensayos cl铆nicos. Los inversores y analistas interesados pueden registrarse enviando un correo a [email protected].
Instil Bio (雮橃姢雼�: TIL)瓿� ImmuneOnco Biopharmaceuticals (頇嶌僵歃濌秾瓯半灅靻�: 1541.HK)電� 2025雲� 5鞗� 31鞚� 鞁滌勾瓿犾棎靹� 韴瀽鞛� 氚� 鞎犽剱毽姢韸� 臁办艾 頄夓偓毳� 瓿惦彊 臧滌禍頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 頄夓偓電� 鞓れ爠 8鞁滊秬韯� 9鞁� 30攵勱箤歆� CT 鞁滉皠鞙茧 McCormick 旎菠靺� 靹柬劙 鞚戈芳鞐愳劀 鞐措Μ氅�, 須岇偓 瓴届榿歆勱臣 氅挫棴膦呾枒頃� 攵勳暭鞚� 欤检殧 鞚橁铂 毽崝臧� 彀胳劃頃� 鞓堨爼鞛呺媹雼�. PD-(L)1xVEGF 鞚挫韸轨澊頃泊 攵勳暭鞕� 鞛勳儊鞁滍棙 斓滌嫚 鞝曤炒毳� 雲检潣頃� 鞓堨爼鞛呺媹雼�. 甏�鞁� 鞛堧姅 韴瀽鞛愳檧 鞎犽剱毽姢韸鸽姅 [email protected]鞙茧 霌彪頃� 靾� 鞛堨姷雼堧嫟.
Instil Bio (Nasdaq : TIL) et ImmuneOnco Biopharmaceuticals (HKEX : 1541.HK) ont annonc茅 qu'ils co-organiseront un petit-d茅jeuner pour investisseurs et analystes 脿 Chicago le 31 mai 2025. L'茅v茅nement, pr茅vu de 8h00 脿 9h30 heure centrale, se tiendra pr猫s du McCormick Convention Center et r茅unira la direction des entreprises ainsi qu'un expert reconnu en immuno-oncologie. Ils aborderont le paysage des anticorps bisp茅cifiques PD-(L)1xVEGF et fourniront des mises 脿 jour sur les essais cliniques. Les investisseurs et analystes int茅ress茅s peuvent s'inscrire en envoyant un courriel 脿 [email protected].
Instil Bio (Nasdaq: TIL) und ImmuneOnco Biopharmaceuticals (HKEX: 1541.HK) haben angek眉ndigt, dass sie am 31. Mai 2025 ein gemeinsames Fr眉hst眉cksevent f眉r Investoren und Analysten in Chicago veranstalten werden. Die Veranstaltung findet von 8:00 bis 9:30 Uhr CT in der N盲he des McCormick Convention Centers statt und umfasst das Management der Unternehmen sowie einen f眉hrenden Experten im Bereich Immunonkologie. Es werden die Entwicklungen im Bereich der PD-(L)1xVEGF bispezifischen Antik枚rper sowie Updates zu klinischen Studien vorgestellt. Interessierte Investoren und Analysten k枚nnen sich per E-Mail an [email protected] anmelden.
- None.
- None.
DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, 鈥淚mmuneOnco鈥�), today announced that they will jointly host an investor and research analyst breakfast in Chicago, Illinois on Saturday, May 31, 2025 at 8:00 to 9:30 am CT adjacent to the McCormick Convention Center.
Instil and ImmuneOnco management, along with a key opinion leader in the field of immuno-oncology, will discuss the evolving PD-(L)1xVEGF bispecific antibody聽landscape and recent clinical trial updates from Instil and ImmuneOnco.
Investors and analysts interested in attending should register by emailing their contact information to reserve seating to .
About ImmuneOnco
ImmuneOnco is a clinical-stage biotech company focused on discovery and development of biologics to treat cancers, autoimmune diseases and metabolic diseases. With 10+ assets all originated in-house and the most advanced asset in phase III right now, ImmuneOnco is pursuing innovative therapies to improve patients鈥� health. For more information visit .
About Instil Bio
Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information, visit聽.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.
Contacts:
Investor Relations:
1-972-499-3350
FAQ
When and where is Instil Bio (TIL) hosting its investor breakfast during ASCO 2025?
What topics will be discussed at the Instil Bio (TIL) ASCO 2025 investor event?
How can investors register for Instil Bio's ASCO 2025 breakfast meeting?
Who will be presenting at the Instil Bio (TIL) ASCO 2025 investor breakfast?
